行業機構報告:華為、OPPO及Vivo較受中國疫情衝擊
行業研究機構Counterpoint發表報告,中國智能手機首季銷售受疫情影響而大減,華為將是最受衝擊的手機生產商之一,OPPO及Vivo亦因高度依賴線下銷售渠道而受影響。小米(01810.HK)、一加及Realme受影響程度較低,因該等公司更著重網售及海外市場。
機構下調疫情期間中國線下智能手機銷量預測一半,並下調首季整體銷量預測兩成。機構預期疫情將於3月受控,但中國商業活動完全恢復正常可能需要兩個月,預計中國及全球首兩季智能手機市場將出現負增長。
該機構亦預計疫情使蘋果iPhone銷量減少100萬部。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.